Navigation Links
InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011
Date:11/8/2011

essfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xi) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Registration Statement on Form S-1 filed with the SEC on October 12, 2011. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Company Contact:
www.inspire-md.com
Jonina Ohayon
Marketing Director
jonina@inspire-md.com
OTC BB: NSPR

Investor Contact:
Jeffrey Stanlis
Partner, Hayden IR
jeff@haydenir.com
+1-602-476-1821


'/>"/>
SOURCE InspireMD, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
2. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
3. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
4. InspireMD Boosts MGuard Production Capacity
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference
7. InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
9. InspireMD Announces Year-to-Date 2011 Progress
10. InspireMD Broadens Global Distribution Network; Signs Distributor for the Russian Federation
11. Sol J. Barer, Ph.D. Joins InspireMD Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 Transparency Market Research (TMR) ... " Cancer Diagnostics Market - Global Industry Analysis, Size, ... . According to this report, the global cancer diagnostics market ... the forecast period of 2014 to 2020. In 2013, the ... is expected to be worth US$168,649.3 million by 2020.The increasing ...
(Date:7/28/2015)... CONSHOHOCKEN, Pa. , July 28, 2015 ... the keynote address at Good Neighbor Pharmacy,s 2015 ... 29 to Aug. 1 in Las Vegas, Nev. ... on CNN,s television-show, "Somebody,s Gotta Do It," and Discovery Channel,s, ... country to celebrate the nation,s  "unsung heroes" – people whose ...
(Date:7/28/2015)... July 28, 2015 VirtualScopics, Inc. (NASDAQ: ... solutions, today announced that it will report its second ... market close on Tuesday, August 11, 2015.  Eric ... Jim Groff , chief financial officer, will host ... financial results and provide a business update at 4:30 ...
Breaking Medicine Technology:Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 3Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 4Mike Rowe to Address Community Pharmacists at ThoughtSpot 2015 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 2VirtualScopics, Inc. Schedules Second Quarter 2015 Financial Results Press Release, Conference Call And Webcast 3
... Calif., May 18, 2011 Bayer HealthCare Pharmaceuticals, ... ONXX ) today announced results from a Phase ... with locally advanced or metastatic breast cancer previously ... Nexavar was associated with statistically significant improvements in ...
... SEATTLE, May 18, 2011 Dendreon Corporation (Nasdaq: ... poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and ... upcoming American Society for Clinical Oncology annual meeting in Chicago, ... on Monday, June 6, 2011, from 8:00 a.m. to 12:00 ...
Cached Medicine Technology:Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 2Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 3Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 4Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 5Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 6Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 7Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study 8Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 2Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 3Dendreon Announces Clinical Trial Plans for PROVENGE and DN24-02 at the American Society of Clinical Oncology Annual Meeting 4
(Date:7/28/2015)... ... July 28, 2015 , ... opaJUMP! and O-PA! ... produce health outcomes associated with its training methods. This company is also the ... pre-post study, conducted in early 2015, training yielded an average 80% improvement in ...
(Date:7/28/2015)... Boulder, Colorado (PRWEB) , ... July 28, 2015 , ... ... music, with inspiration taken from influences around the world, in this collection of serene, ... deeply relaxing backgrounds for sleep, for yoga practice, for body work and more -- ...
(Date:7/28/2015)... ... July 28, 2015 , ... Egg freezing is becoming an ... ensure future fertility. As Dr. Michael Kettel explained in an article from ... that wasn’t available for previous generations who had to make choices between their fertility ...
(Date:7/28/2015)... , ... July 28, 2015 , ... According to ... to stop the cycle of addiction in lab mice. The study involving isradipine has ... the new prospect of helping their clients overcome drug and alcohol addictions. The study ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... On July ... officials refused to schedule the hearing of proposed bills and laws revolving the implementation ... new infections to date. Some vigilante ministers are continuing to hand out clean needles ...
Breaking Medicine News(10 mins):Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 2Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 3Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 4Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 5Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 6Health News:opaJUMP Launches First Case Study in Thyroid Health: How Rebounding Helped One Woman Stabilize Her Thyroid in Seven Weeks 7Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 2Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 3Health News:Flute Meditations for Yoga & Massage: Calming Spa Music for Relaxation & Sleep by Gary Stroutsos 4Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 2Health News:Dr. Michael Kettel of San Diego Fertilty Center Interviewed by the San Diego Union-Tribune on Egg Freezing 3Health News:Blood Pressure Medication May be the Key to Treating Addiction 2Health News:Blood Pressure Medication May be the Key to Treating Addiction 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3
... 25 Sikorsky Aircraft Corp. and,customer PHI, Inc. ... for the PHI fleet, and the milestone achievement ... at a ceremony today at,Heli-Expo. Sikorsky Aircraft is ... ), (Logo: http://www.newscom.com/cgi-bin/prnh/20060403/SIKORSKYLOGO ), ...
... Oregon Health & Science University Cancer Institute researchers, ... with advanced prostate cancer can take a much-needed safe ... study, led by principal investigator Tomasz Beer, M.D., recently ... Grover C. Bagby Endowed Chair for Cancer Research, director ...
... WASHINGTON, Feb. 25 In response to ... bundling report,released earlier this week, Kidney Care Partners ... care providers and manufacturers,working together to improve quality ... failure -- applauds CMS for issuing its long-awaited,report ...
... February 25, 2008 Cases of esophageal cancer (adenocarcinoma) in ... in 1973 to 2.1 million in 2001 at age-adjusted rates. ... shows that these rates in the U.S. closely mirrored trends ... study illustrates what may be a public heath concern as ...
... CDC Alerting Services Use Service-Oriented Architecture, ... CBR ) has,successfully designed, built, and ... CDC Alerting Service,(CDCAS) for the Centers for ... and quickly alerts public health officials and ...
... Impacts, What Needs ... Be Done, WASHINGTON, Feb. 25 , WHAT: The Association of Schools of Public ... health workforce shortage -- the first of its kind ... findings and recommended actions., WHY: The U.S. faces a public health workforce crisis, and ...
Cached Medicine News:Health News:Sikorsky Aircraft and PHI Celebrate Fleet Expansion and 20K Milestone at Heli-Expo 2Health News:OHSU Cancer Institute research gives hope for chemo holidays for men with advanced prostate cancer 2Health News:Statement by Dr. Edward Jones, Chairman of Kidney Care Partners in Response to CMS Payment Bundling Report 2Health News:Statement by Dr. Edward Jones, Chairman of Kidney Care Partners in Response to CMS Payment Bundling Report 3Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 2Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 3Health News:CDC Uses CIBER-Built Solution to Alert Public Health Officials and Public Health Departments 4Health News:New Assessment Highlights Breadth and Depth of Looming Public Health Workforce Crisis 2
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
Malaria device / strip (3 line, P.f/P.v Ag Test-pLDH)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: